Similar articles

• Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.

  Morimoto M, Yoshioka Y, Konishi K, Isohashi F, Takahashi Y, Ogata T, Koizumi M, Teshima T, Bijl HP, van der Schaaf A, Langendijk JA, Ogawa K. Morimoto M, et al. Tumori. 2014 May-Jun;100(3):265-71. doi: 10.1700/1578.17198. Tumori. 2014. PMID: 25076236
• Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.

  Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Vora SA, et al. J Urol. 2013 Aug;190(2):521-6. doi: 10.1016/j.juro.2013.02.012. Epub 2013 Feb 13. J Urol. 2013. PMID: 23415964
• High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

  Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. Zelefsky MJ, et al. J Urol. 2001 Sep;166(3):876-81. J Urol. 2001. PMID: 11490237
• Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

  Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Pollack A, et al. World J Urol. 2003 Sep;21(4):200-8. doi: 10.1007/s00345-003-0356-x. Epub 2003 Sep 5. World J Urol. 2003. PMID: 12961097 Review.
• The treatment of non-metastatic prostate cancer with external beam radiation therapy.

  Horwitz EM, Feigenberg SJ, Uzzo RG. Horwitz EM, et al. Minerva Urol Nefrol. 2004 Jun;56(2):173-88. Minerva Urol Nefrol. 2004. PMID: 15195025 Review.